Publication | Open Access

Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)

DysbiosisPhase Ii TrialMedicineColorectal CancerPathologyMicrobiologyGut BarrierMicrobiomeOncologyRadiation OncologyFecal Microbiota Transplantation